Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer

Independent validation of EarlyR gene signature in E2197: a randomized clinical trial comparing doxorubicin plus docetaxel to doxorubicin plus cyclophosphamide as adjuvant chemotherapy in breast cancer

S Badve;V Wang;S Willis;B Leyland-Jones;Y Gokmen-Polar;LN Shulman;S Martino;J Sparano;E Perez;N Davidson;L Goldstein;S Buechler San Antonio Breast Cancer Symposium (December 5-9, 2017, San Antonio, TX), poster

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

S Adams;RJ Gray;S Demaria;L Goldstein;EA Perez;LN Shulman;S Martino;M Wang;V Jones;T Saphner;A Wolff;W Wood;NE Davidson;G Sledge;J Sparano;S Badve Journal of Clinical Oncology 32(27):2959-2967;

PMid: PMID25071121 | PMC number: PMC4162494

Prognostic value of tumor-infiltrating lympocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

S Adams;R Gray;S Demaria;LJ Goldstein;EA Perez;LN Shulman;S Martino;NE Davidson;G Sledge;J Sparano;S Bavde San Antonio Breast Cancer Symposium, abst S1-07; oral presentation;

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197

L Solin;R Gray;L Goldstein;A Recht;F Baehner;S Shak;S Badve;E Perez;LN Shulman;S Martino;NE Davidson;G Sledge;JA Sparano Breast Cancer Research and Treatment 134(2):683-692

PMid: PMID22547108 | PMC number: PMC3552372

Gene expression profiling of phenotypically-defined hormone-receptor positive breast cancer: evidence for increased transcriptional activity of the insulin growth factor receptor pathway and other pathways

J Sparano;RG Gray;LJ Goldstein;BH Childs;D Brassard;R Bugarini;S Rowley;J Baker;S Shak;S Badve;FL Baehner;P Kenny;E Perez;LN Shulman;S Martino;G Sledge;NE Davidson San Antonio Breast Cancer Symposium, abstract #5165, poster presentation

Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer

J Sparano;L Goldstein;B Childs;S Shak;D Brassard;S Badve;F Baehner;R Bugarini;S Rowley;E Perez;L Shulman;S Martino;NE Davidson;G Sledge;R Gray Clinical Cancer Research 15(24):7693-7700

PMid: PMID19996222 | PMC number: PMC3396025

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory [PMID 18487567]

SS Badve;FL Baehner;RP Gray;BH Childs;T Maddala;ML Liu;SC Rowley;S Shak;ED Perez;LJ Shulman;S Martino;NE Davidson;GW Sledge;LJ Goldstein;JA Sparano Journal of Clinical Oncology 26(15):2473-2481

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

L Goldstein;A O'Neill;J Sparano;E Perez;L Shulman;S Martino;NE Davidson Journal of Clinical Oncology 26(25):4092-4099

PMid: PMID18678836 | PMC number: PMC2654376

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

L Goldstein;R Gray;S Bavde;B Childs;C Yoshizawa;S Rowley;S Shak;FL Baehner;P Ravdin;NE Davidson;GW Sledge;E Perez;L Shulman;S Martino;J Sparano Journal of Clinical Oncology 26(25):4063-4071

PMid: PMID18678838 | PMC number: PMC2654377

Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197

SS Badve;FL Baehner;B Childs;T Maddala;S Rowley;S Shak;N Davidson;LJ Goldstein;J Sparano Journal of Clinical Oncology 25(18S):21022

LVEF assessment of adjuvant doxorubicin/cyclophosphamide (AC) vs doxorubicin/docetaxel (AT) in early stage breast cancer: cardiac safety results of ECOG 2197.

LJ Goldstein;A O'Neill;JA Sparano;EA Perez;LN Shulman;S Martino;AC Wolff;NE Davidson Proc of the American Society of Clinical Oncology 22:19(#73)